1350 S. LOOP ROAD, ALAMEDA, CA
Investor Presentation
Reports Second Quarter 2026 Financial Results and Provides Business Update
Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Material Contracts, Other Events
Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Reports First Quarter 2026 Financial Results and Provides Business Update
Q2
Q1
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
SEC Form 25 - Delisting Notification
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload